SIK1 Inhibitors
1 drugsAbout SIK1
Salt-inducible kinase 1 (SIK1) is a serine/threonine kinase involved in cellular metabolism, stress response, and immune function. While its precise mechanisms are still being investigated, SIK1's role in these pathways makes it a potential drug target.
SIK1 is an emerging oncology target, though no genetic evidence currently links it to specific diseases. The existence of an approved drug suggests that modulating SIK1 activity can have therapeutic benefits in cancer.
SIK1 is currently targeted by one FDA-approved small molecule drug, TAFINLAR (Novartis), which has 4 indications in oncology. This single drug represents the entire current therapeutic landscape for SIK1.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Advanced Lymphoma with only 2 trials.
- phase1 represents biological uncertainty with 55% completion.
Top Drugs
Novartis is the only company with an approved drug targeting SIK1.
The lack of competition presents an opportunity for other companies to enter the SIK1 therapeutic space.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SIK1, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage and expand therapeutic options.
Clinical Trials 131 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 47 | 25 | 13 | 8 | 66% |
| Phase 2 | 60 | 21 | 16 | 23 | 57% |
| Phase 3 | 18 | 12 | 1 | 5 | 92% |
| Phase 4 | 6 | 1 | 1 | 3 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2013 - 2013)
The first and only drug targeting SIK1, TAFINLAR, was approved in 2013.
The absence of recent approvals suggests a potential saturation or a need for novel approaches to target SIK1.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 84 clinical trials targeting SIK1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities